Hôpital Européen Georges-Pompidou   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3
Founded: Paris France

Organization Overview

First Clinical Trial
2005
NCT03362684
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

AP-HP, Hôpital Européen Georges Pompidou, Paris | European Hospital Georges Pompidou | HOPITAL EUROPEEN GEORGES POMPIDOU | Hôpital Européen Georges-Pompidou | Hôpital Européen Georges Pompidou, Oncology department of Pr Stéphane OUDARD | Hôpital Européen Georges Pompidou, Paris, France | Medicine interne department, Europeen Georges Pompidou Hospital, Paris, France | Plateforme labellisée Inca – Hôpital Européen Georges Pompidou, Paris

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Transitional Cell (Phase 2)

Colorectal Neoplasms (Phase 3)

Oropharyngeal Neoplasms (Phase 2)

Sarcoma (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 27